Barbara Pescitelli, NP
Adult Health · Greenfield, INNPI 1154398154
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 186 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 9.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $989, 2.1 times the $463 reported in 2021.
Across 186 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$346
- Regeneron Healthcare Solutions, Inc.$313
- Grifols USA, LLC$280
- AbbVie$270
- Novo Nordisk$225
- Lilly USA, LLC$193
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,648100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 16 | $346 |
| Regeneron Healthcare Solutions, Inc. | 13 | $313 |
| Grifols USA, LLC | 11 | $280 |
| AbbVie | 14 | $270 |
| Novo Nordisk | 13 | $225 |
| Lilly USA, LLC | 10 | $193 |
| Boehringer Ingelheim | 8 | $188 |
| Sanofi | 9 | $176 |
| Exact Sciences | 9 | $173 |
| GSK | 9 | $159 |
| Abbott | 8 | $130 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $126 |
| Amgen | 6 | $99 |
| Merck | 5 | $86 |
| Mylan Specialty L.p. | 5 | $80 |
| Philips North America LLC | 5 | $78 |
| Astellas Pharma US Inc | 3 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $58 |
| Pfizer | 4 | $58 |
| Mallinckrodt Hospital Products Inc. | 2 | $50 |
| Baxter Healthcare | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Dexcom, Inc. | 2 | $44 |
| Bayer | 2 | $40 |
| Novartis | 2 | $40 |
| Gilead | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Verona Pharma, Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Viatris Specialty LLC | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Pulmonx Corporation | 1 | $19 |
| Insmed, Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$3,648 in reported general payments places this provider in the 85th percentile of 391 adult health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 48 | $53,543 |
| RybelsusSemaglutide | 14 | $38,219 |
| XareltoRivaroxaban | 34 | $32,116 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 142 | $31,417 |
| JardianceEmpagliflozin | 32 | $30,218 |
| FarxigaDapagliflozin Propanediol | 17 | $26,497 |
| JanuviaSitagliptin Phosphate | 19 | $23,773 |
| MyrbetriqMirabegron | 26 | $19,747 |
| OzempicSemaglutide | 20 | $19,375 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $16,669 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 20 | $16,345 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 51 | $16,192 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $13,271 |
| MounjaroTirzepatide | 12 | $13,027 |
| TrulicityDulaglutide | 11 | $12,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $58 | $69,73599 claims |
| GSKShingrix, Trelegy Ellipta, Breo Ellipta | $159 | $61,358182 claims |
| Novo NordiskRybelsus, Ozempic | $225 | $57,59534 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $188 | $51,39956 claims |
| AstraZenecaFarxiga | $346 | $26,49717 claims |
| Lilly USA, LLCMounjaro, Trulicity | $193 | $25,04123 claims |
| MerckJanuvia | $86 | $23,77319 claims |
| Astellas Pharma US IncMyrbetriq | $67 | $19,74726 claims |
| AbbVieSynthroid | $270 | $1,30237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 391 adult health providers in Indiana.
Other adult health in Greenfield
- Jolyn Holliday VezaGreenfield$17K
- Jennifer BerryIndianapolis$50K
- Tajuana DavisZionsville$31K
- Patricia Damron-RobinsonMerrillville$20K
- Terry RidgeCarmel$20K
- Kristine StarcevichMerrillville$19K
- Anna MatulewiczMishawaka$14K
- Ludmila Pichugena-EmersonMiddlebury$14K
- Vincent SmithMerrillville$13K
- Lisa DankoCrown Point$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.